Intrahepatic Cholangiocarcinoma Associated with Intrahepatic Duct Stones

Hur, Hoon; Park, Il-Young; Sung, Gi-Young; Lee, Dosang; Kim, Wook; Won, Jong-Man

doi:10.1016/s1015-9584(09)60002-6

Cited by 10 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Epidemiological, pathological, and genetic studies have showed the relationship between hepatolithiasis and cholangiocarcinoma [6][7][8]. The presence of cholangiocarcinoma-associated hepatolithiasis is the main factor compromising long-term survival in patients with hepatolithiasis [10] but unfortunately early diagnosis of concomitant cholangiocarcinoma is difficult [11]. Hepatic resection is frequently considered for the definitive treatment of hepatolithiasis, because it can remove stones and stenotic bile duct simultaneously, reduce the risk of recurrent stones and development of cholangiocarcinoma [12][13][14][15].…”

Section: Discussionmentioning

confidence: 99%

“…Stone removal using percutaneous transhepatic choledochoscopic lithotomy (PTCSL) can resolve the cholangitis due to stone [9] and also surgical treatment such as hepatic resection can eliminate the inflammatous hepatic segment including stones [10]. Despite the various efforts to remove the stones and advances in diagnostic modality, early diagnosis of cholangiocarcinoma is still challenging in these patients [11].There have been insufficient data regarding the long-term outcome of hepatectomy as the treatment modality of hepatolithiasis. Furthermore, the literature contains few data for occurrence of cholangiocarcinoma after treatment of hepatolithiasis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cholangiocarcinoma Risk as Long‐term Outcome After Hepatic Resection in the Hepatolithiasis Patients

Kim

Suh

et al. 2015

World j. surg.

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Cholangiocarcinoma Risk as Long‐term Outcome After Hepatic Resection in the Hepatolithiasis Patients

Kim

Suh

et al. 2015

World j. surg.

View full text Add to dashboard Cite

show abstract

“…There are several documented risk factors for ICC, including primary sclerosing cholangitis, liver fluke infection ( Clonorchis sinensis or Opisthorchis viverrini ), fibropolycystic liver disease, hepatolithiasis, and thorotrast exposure [6–8]. Exendin-4 is a 39-amino acid glucagon-like peptide-1 (GLP-1) analog, which was found originally in the saliva of the gila monster.…”

Section: Introductionmentioning

confidence: 99%

Effect of the GLP-1 Analog Exendin-4 and Oxaliplatin on Intrahepatic Cholangiocarcinoma Cell Line and Mouse Model

Chen

Zhao

Jia

et al. 2013

IJMS

View full text Add to dashboard Cite

The influence of Glucagon-like peptide-1 (GLP-1) and Exendin-4 on development of intrahepatic cholangiocarcinoma (ICC) is evaluated in the study. In vitro tests, including acute toxicity test, cell colony formation assays, cells proliferation and apoptosis, transwell assay, were performed. An ICC in situ tumor animal model was established. Then, animals were randomly divided into four groups (n = 6): control, Exendin-4 treatment, oxaliplatin treatment and Exendin-4-oxaliplatin treatment. Animals in the Exendin-4 treatment and Exendin-4-oxaliplatin treatment groups received a subcutaneous injection of Exendin-4 (100 μg/kg/day) for 1 week, and then received oxaliplatin (10 mg/kg/week) by tail vein injection. Animals in the control group received PBS. Immunohistochemistry tests were used for PCNA, Ki67, Caspase 3 expression in tumor tissue. Results show that that, after incubation of human cholangiocarcinoma cell lines, HuCCTI and GLP-1, or HuCCTI and Exendin-4, colony formation number was sharply decreased. However, GLP-1, HuCCTI or Exendin-4 did not affect the colony of normal cells. Combination treatment with oxaliplatin and Exendin-4 can significantly inhibit tumor cells’ proliferation and promote apoptosis. The combined effect is stronger than that of oxaliplatin or Exendin-4. Combination treatment with oxaliplatin and Exendin4 can significantly decrease Ki67 and PCNA proteins’ expression in subcutaneous tumors of nude mice. The inhibitory effect of Combination treatment with oxaliplatin and Exendin4 is clearly stronger than that of oxaliplatin. In addition, Combination treatment with oxaliplatin and Exendin4 can significantly increase Caspase3 protein positive expression. In short, these results show that combination treatment with oxaliplatin and Exendin4 can inhibit tumor cells’ proliferation, and promote apoptosis.

show abstract

The growth-inhibition effect of tamoxifen in the combination chemotherapeutics on the human cholangiocarcinoma cell line QBC939

Liu

Qin

2009

Mol Biol Rep

View full text Add to dashboard Cite

In the individual application of adriamycin, mitomycin, vindesine and their combined application with tamoxifen for the pre-treatment of the human cholangiocarcinoma cell line QBC939, QBC939 was determined by MTT assay to investigate the inhibitive effect and its initial mechanism of TAM on cell growth. Growth cycle and apoptosis of each group were determined by flow cytometry. Concentration of ADM in QBC939 was detected by flow cytometry. The levels of their P-glycoprotein were detected by immunohistochemistry. The mRNA and protein levels of apoptotic-associated genes Bcl-2 and Bax were determined by western blot and real-time PCR. The inhibitive rates of adriamycin, mitomycin, vindesine to QBC939 and the apoptosis rates of QBC939 were enhanced after the pre-treatment of tamoxifen. Influence of tamoxifen in their growth cycle was not so obvious except vindesine group because of the increasing cell numbers of G (2)/M phase in which cells may be blocked. The contents of adriamycin in cells rose after the pre-treatment of tamoxifen. Expression level of the multi-drug resistant protein on cell surface was shown as (+). Furthermore, real-time PCR and Western blot analysis revealed an upregulation of Bcl-2 and a downregulation of Bax in QBC939 after the pre-treatment of tamoxifen. Therefore, tamoxifen may have the ability to enhance the relative sensitivity of QBC939 to chemotherapeutics.

show abstract

Intrahepatic Cholangiocarcinoma Associated with Intrahepatic Duct Stones

Abstract: IHCC with IHDS was difficult to diagnose in the early phase. Therefore, while performing diagnostic studies and surgery for IHDS, one should always consider the possibility of coexisting cholangiocarcinoma.

Cited by 10 publications

References 30 publications

Cholangiocarcinoma Risk as Long‐term Outcome After Hepatic Resection in the Hepatolithiasis Patients

Cholangiocarcinoma Risk as Long‐term Outcome After Hepatic Resection in the Hepatolithiasis Patients

Effect of the GLP-1 Analog Exendin-4 and Oxaliplatin on Intrahepatic Cholangiocarcinoma Cell Line and Mouse Model

The growth-inhibition effect of tamoxifen in the combination chemotherapeutics on the human cholangiocarcinoma cell line QBC939

Contact Info

Product

Resources

About